Wound Care Market

On 31 October 2025, the US Centers for Medicare & Medicaid Services finalised a rule that, from 1 January 2026, pays for most skin substitutes used on chronic wounds as a single flat rate per square centimetre instead of product-by-product prices, ending a payment gap that had let Medicare spending on these products multiply in five years. The rate was set at USD 127.28 per square centimetre and corrected to USD 127.14 in November 2025, a fraction of what many placental and tissue grafts had been billing. Douglas Insights values the wound care market at USD 23.9 billion in 2025 and forecasts USD 39.0 billion by 2035, a compound growth rate of 5.05%. The receipt is about 412 million treated wound episodes in 2025 at an average product spend of USD 57.90 per episode across dressings, negative-pressure devices and biologics. Episodes grow 3.6% a year as diabetes, ageing and surgery add wounds; spend per episode grows 1.4% a year as advanced dressings and single-use devices replace gauze, partly offset by lower biologic prices. The report sits within Douglas Insights coverage of medical devices and follows the published Douglas Insights research methodology.

What does the wound care market include?

The wound care market covers products used to treat acute and chronic wounds, about 412 million treated episodes worth USD 23.9 billion in 2025. Traditional dressings and basic care include gauze, bandages, tapes and simple cleansers. Advanced dressings include foams, hydrocolloids, alginates, hydrogels, films and antimicrobial dressings with silver, iodine or honey; silver is also the leading additive in the Antibacterial Plastics Market report. Negative-pressure wound therapy (NPWT) devices and consumables apply suction to draw fluid from wounds and speed healing, from hospital rental units to single-use pocket devices. Biologics, skin substitutes and sealants include placental membranes, cellular and tissue products, engineered skin and surgical sealants. The market spans diabetic foot ulcers, pressure and venous ulcers, surgical and trauma wounds and burns, treated in hospitals, post-acute and community care, and home and self-care. Sutures, staples, compression garments sold alone and ostomy products sit outside the boundary, as do cosmetic resurfacing devices, which are sized in the Medical Aesthetic Devices Market report.

How does the Medicare skin substitute reform change wound care?

The Medicare skin substitute reform cuts the price of most biologic wound products in the United States, and Douglas Insights estimates it cuts the average US payment per skin substitute application by about 40% to 60%, which holds global biologics growth to 4.7% a year as rising volumes only partly offset lower prices. The CMS fact sheet on the CY 2026 Physician Fee Schedule final rule set out the change, which treats most skin substitutes as supplies furnished with an application procedure rather than as separately priced biologicals; products licensed as biologics under section 351 of the Public Health Service Act keep average-sales-price payment. The reform followed a government audit finding that Medicare spending on skin substitutes had risen by more than 640% in two years. Douglas Insights threads the reform through this report: it resets the biologics segment, it shifts spending back toward advanced dressings and negative pressure, and future rate changes and coverage rules are the main swings in the scenarios.

Why do chronic wounds drive the wound care market?

Chronic wounds drive the wound care market because they last for months and consume products every few days, and Douglas Insights estimates chronic ulcers made up about 22% of episodes but 58% of product spending in 2025. A diabetic foot ulcer can take 12 to 20 weeks to heal, needing two or three dressing changes a week, offloading, infection control and sometimes negative pressure or grafts; correcting anaemia, covered in the Iron Supplements Market report, is often part of the plan. About 537 million adults had diabetes in 2021, according to the International Diabetes Federation (the same epidemic drives the kidney failure sized in the Dialysis Equipment Market report), and up to a third of them will develop a foot ulcer in their lifetime. Pressure ulcers in immobile patients and venous leg ulcers in older adults add a large, steady caseload in care homes and community nursing.

What drives wound care demand to 2035?

Four drivers carry wound care episode growth of 3.6% a year, and diabetes is the largest. Diabetic foot ulcers are the most expensive common wound and a leading cause of amputation. Douglas Insights values diabetic foot ulcer care at USD 7.16 billion in 2025, 30% of the market, and estimates that each additional 10 million people with diabetes add about 1 million treated foot ulcer episodes a year. The International Diabetes Federation projects the number of adults with diabetes to rise toward 780 million by 2045, with the fastest growth in Asia, the Middle East and Africa, where access to advanced wound care is still limited.

Ageing is the second driver. Pressure and venous ulcers rise sharply after 70, and the number of people over 80 worldwide is set to roughly double by 2050. Douglas Insights values pressure and venous ulcer care at USD 6.68 billion in 2025, growing about 5% a year, with care homes and community nurses the main buyers. Pressure ulcers are treated as a measure of care quality in many countries, and hospitals that report them face penalties or public scrutiny, which keeps demand for prevention dressings and specialist mattresses high.

Care-setting migration is the third driver. Health systems are moving wound care out of hospitals into clinics and homes, where single-use negative-pressure devices and simple advanced dressings let patients heal without long stays. Douglas Insights values NPWT devices and consumables at USD 4.77 billion in 2025, growing 6.8% a year, the fastest of any product, and estimates single-use devices will pass half of NPWT value by 2030. Home health agencies and community nurses in the United States, the United Kingdom and Germany now manage a growing share of complex wounds that once kept patients in hospital for weeks.

Surgical volumes are the fourth driver. More than 300 million operations are performed worldwide each year, and surgical site infection and wound breakdown add cost to many of them. Douglas Insights values surgical and trauma wound care at USD 8.11 billion in 2025 and estimates closed-incision negative pressure and antimicrobial dressings add about 0.3 points a year to spend per episode. Hospitals in the United States face penalties for readmissions after some operations, including vascular access surgery for the patients counted in the Dialysis Equipment Market report, which makes a USD 200 dressing that prevents an infection an easy purchase.

What could restrain wound care sales?

Three restraints remove about 0.8 points a year from wound care growth. Payment reform is the first. The US skin substitute rule, tighter coverage reviews and similar price controls in Europe cut prices for premium products. Douglas Insights holds spend per episode growth at 1.4% a year, below mix-driven growth of about 2.2%, to reflect these cuts.

Commodity pressure is the second restraint. Traditional dressings are bought through tenders and group purchasing organisations, and low-cost suppliers in China and India compete hard. Douglas Insights models traditional dressings growing only 2.8% a year, the slowest of any segment. Large buying groups in the United States and national tenders in Europe often award contracts on price alone, which squeezes margins even for branded advanced dressings once their patents and clinical advantages age.

Prevention is the third restraint. Better diabetic foot screening, pressure-relieving mattresses and early compression therapy can prevent wounds before they start. Douglas Insights estimates that wide adoption of prevention programmes could cut chronic ulcer incidence by 10% to 20% in health systems that fund them, which is built into the lower scenario.

Which wound care segment carries the value, advanced dressings or traditional gauze?

Advanced dressings lead the wound care market with 38% of 2025 value, while NPWT devices and consumables are the fastest-growing segment at 6.8% a year. In between, traditional and basic care holds USD 5.73 billion on sheer volume, and biologics and skin substitutes hold USD 4.29 billion after the 2026 payment reset. Every product holds its share for a different reason.

Advanced dressings are worth USD 9.07 billion in 2025. They lead because foams, alginates and antimicrobial dressings are the standard treatment for most chronic wounds and are changed several times a week.

Traditional and basic care is worth USD 5.73 billion in 2025. Gauze and bandages are still used everywhere, but low prices and substitution by advanced products hold growth to 2.8% a year.

NPWT devices and consumables are worth USD 4.77 billion in 2025 and form the fastest-growing segment at 6.8% a year, because single-use pocket devices let patients go home with therapy.

Biologics and skin substitutes are worth USD 4.29 billion in 2025. The US payment reform resets prices in 2026, but volume keeps growing for hard-to-heal ulcers and burns, so the segment recovers to 4.7% a year.

How do wound type and care setting split the wound care market?

By wound type, surgical and trauma wounds account for USD 8.11 billion (34%) of 2025 value, diabetic foot ulcers for USD 7.16 billion (30%), pressure and venous ulcers for USD 6.68 billion (28%), and burns for USD 1.91 billion (8%). By care setting, hospitals account for USD 11.2 billion (47%), post-acute and community care for USD 7.40 billion (31%), and home and self-care for USD 5.25 billion (22%).

How is single-use negative pressure changing wound care?

Single-use negative pressure is changing wound care by moving a hospital therapy into clinics and homes, and Douglas Insights estimates single-use devices made up about 38% of negative-pressure wound therapy value in 2025, up from about 20% in 2018. A traditional NPWT system is a rented pump with canisters, tubes and foam, managed by trained staff; a single-use device is a small battery pump attached to a dressing that runs for seven days and is thrown away. Surgeons increasingly apply single-use devices over closed incisions after caesarean sections, joint replacements and cardiac surgery to lower infection and wound breakdown rates. For suppliers, single-use devices replace rental revenue with product sales and let them reach patients who never enter a hospital wound clinic. For payers, the shift lowers the cost of therapy per episode even as more patients receive it, which is why NPWT grows faster than any other wound care product.

Which regions buy the most wound care?

North America buys 40% of wound care by value, USD 9.54 billion in 2025, while Asia Pacific grows fastest at 6.6% a year. North America leads because it uses the most advanced dressings, negative pressure and biologics per wound. The region grows 4.4% a year, held back by the 2026 skin substitute reset.

Europe buys USD 6.20 billion and grows 4.2% a year, with strong community nursing, tender-based buying and national wound care guidelines that favour advanced dressings.

Asia Pacific buys USD 5.49 billion and grows 6.6% a year, the fastest rate, as China and India, which together have well over 200 million people with diabetes, expand access to advanced wound care. Latin America buys USD 1.43 billion and grows 5.8%. The Middle East is the wildcard at USD 716 million and 6.2% a year, with some of the world’s highest diabetes rates in the Gulf. Africa buys USD 477 million and grows 6.0%.

Who are the leading wound care companies?

Douglas Insights estimates that the three largest wound care companies hold about 27% of 2025 value, led by Solventum at about 11%.

Advantage in wound care rests on clinical evidence and reach into hospitals and community nursing. Solventum leads negative pressure through the KCI franchise; Smith+Nephew pushes single-use devices; Mölnlycke leads European foam dressings; Convatec and Coloplast win in antimicrobial and chronic care. Biologics specialists such as MiMedx and Organogenesis face the biggest impact from the US payment reform, and evidence-backed products are best placed to recover.

How is a wound care episode priced?

Wound care products cost an average of USD 57.90 per treated episode in 2025, and Douglas Insights expects about USD 66.50 by 2035. A simple surgical wound may use USD 5 to USD 20 of dressings, while a diabetic foot ulcer treated for three months can use USD 500 to USD 2,000 of advanced dressings, and several thousand dollars more with negative pressure or grafts. Single-use NPWT devices cost about USD 150 to USD 400 each, and a week of rental therapy USD 700 to USD 1,000. Under the 2026 Medicare rule, a skin substitute application covering 20 square centimetres is paid at about USD 2,540 for the product.

Why are diabetic foot ulcers the centre of the wound care market?

Diabetic foot ulcers take about 30% of wound care spending, USD 7.16 billion in 2025. They are common, slow to heal and costly when they fail, and Douglas Insights estimates they drive a far larger share of total health costs through amputations and hospital stays. About half of diabetic foot ulcers become infected, and around one in five infected ulcers leads to some form of amputation. Health systems that invest in multidisciplinary foot clinics, offloading and early advanced care have cut amputation rates sharply, which is why payers accept higher product spend for these patients. The same logic drove the rise of skin substitutes, and it is why the reformed payment system still pays for them.

Which rules apply to wound care?

Wound care products are regulated as medical devices, and some as biologics or human tissue: dressings and NPWT systems need FDA clearance or CE marking under the EU Medical Device Regulation, while skin substitutes are regulated as devices, biologics or 361 human cell and tissue products depending on how they are made. Payment rules, such as the Medicare skin substitute reform and national tariffs for dressings in Europe, decide which products hospitals and community nurses can afford.

How far could wound care reach under each scenario?

The base scenario takes the wound care market to USD 39.0 billion by 2035, with a range of USD 32.7 billion to USD 43.9 billion. The base case combines 3.6% episode growth with 1.4% spend growth for 5.05% a year. The audit-and-austerity scenario assumes more payment cuts, stronger prevention and tender pressure, setting the legs at 2.6% and 0.6% for USD 32.7 billion. The chronic-tide scenario assumes faster growth in diabetes and ageing and a quicker shift to advanced products, setting the legs at 4.2% and 2.0% for USD 43.9 billion. Each 1-point change in episode growth moves the 2035 figure by about USD 3.94 billion.

Douglas Exclusive: the reimbursement-integrity and episode-cost map

The reimbursement-integrity and episode-cost map records, for 25 countries, payment rules for each wound product type, coverage decisions for skin substitutes, audit findings and the product cost of a typical episode for each wound type and care setting, so suppliers can see where their products will be paid for. Related markets are covered in the Medical Adhesive Transfer Tapes Market and Hospital Sterile Processing Department Equipment Market reports.

Methodology and receipts

The wound care model is built bottom-up from treated episodes. The headline receipt is about 412 million episodes multiplied by USD 57.90 of product spend per episode, giving USD 23.9 billion for 2025. Episodes are estimated for 25 countries from diabetes, ageing and surgery data, ulcer incidence and recurrence rates and treatment rates, and spend per episode from product use by wound type and setting, reconciled with company revenue and Medicare claims data. Product use per episode is built from clinical guidelines and dressing-change frequencies for 12 wound and setting combinations, and biologics are modelled separately under old and new US payment rules so the 2026 reset can be traced. The forecast compounds 3.6% episode growth and 1.4% spend growth from the 2025 base to about 587 million episodes and USD 39.0 billion in 2035.

Sources

1. Centers for Medicare & Medicaid Services Calendar Year (CY) 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) fact sheet (2025)
2. World Health Organization WHO Global Health Observatory: noncommunicable disease indicators (2026)
3. United Nations Statistics Division UN Comtrade: trade flows in wadding, gauze, bandages and dressings (2026)